HC Wainwright Reiterates Buy Rating for Protara Therapeutics (NASDAQ:TARA)

Protara Therapeutics (NASDAQ:TARA – Get Free Report)‘s stock had its “buy” rating reaffirmed by research analysts at HC Wainwright in a research report issued to clients and investors on Monday,Benzinga reports. They currently have a $23.00 price objective on the stock. TARA has been the subject of several other reports. Scotiabank started coverage on shares […]

Apr 30, 2025 - 07:02

Protara Therapeutics (NASDAQ:TARA – Get Free Report)‘s stock had its “buy” rating reaffirmed by research analysts at HC Wainwright in a research report issued to clients and investors on Monday,Benzinga reports. They currently have a $23.00 price objective on the stock. TARA has been the subject of several other reports. Scotiabank started coverage on shares […]